{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.4","upperLimit":"90.0","value":"87.5"},{"groupId":"OG001","lowerLimit":"79.6","upperLimit":"88.4","value":"84.6"}]}],"title":"12-months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.9","upperLimit":"71.9","value":"68.1"},{"groupId":"OG001","lowerLimit":"59.6","upperLimit":"71.2","value":"65.8"}]}],"title":"24-months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.5","upperLimit":"61.0","value":"56.9"},{"groupId":"OG001","lowerLimit":"43.5","upperLimit":"55.7","value":"49.7"}]}],"title":"36-months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"532"},{"groupId":"OG001","value":"262"}],"units":"Participants"}],"description":"Overall survival rate is defined as the percentage of participants who are alive at 1, 2 and 3 years following randomization","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240 mg Q2W for 8 cycles (16 weeks) followed by Nivolumab 480 mg Q4W for 9 cycles.","id":"OG000","title":"Nivolumab"},{"description":"Placebo IV Q2W for 8 cycles (16 weeks) followed by Placebo IV Q4W for 9 cycles","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"At 12-, 24- and 36-months post first dose.","title":"Overall Survival Rates at 12-, 24-, and 36-months","type":"SECONDARY","unitOfMeasure":"Percent of participants"}